225625
Allied Corp. Featured on Laurence Fishburne Television Segment Released to Public TV

Nov 3, 2020

Suite 201 – 1405 St. Paul Street
Kelowna, BC, Canada V1Y 2E9
Toll Free: 1-877-255-4337
www.allied.health


Allied Corp. Featured on Laurence Fishburne Television Segment Released to Public TV Across the US

Kelowna, BC, Canada – November 02, 2020 – Allied Corp. ("Allied") (OTCQB: ALID) – an in-ternational medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce that the nationally distributed television program, Behind the Scenes with Laurence Fishburne has been completed and has now been distributed.

The Allied segment is expected to air on television programs across the United States 45 to 60 times per quarter and will be distributed to roughly 60 million households. The program is hosted by Laurence Fishburne (John Wick 2, Mystic River, King of New York and Boyz n the Hood). The content highlights the need for awareness around the PTSD epidemic and suicide rates in the veteran and first responder cohorts. Allied’s intent is to help those suffering with modern health issues gain access to holistic healing modalities. The segment is approximately five minutes and is meant to provide television programmers content that can be added to 25 minute and 55 minute shows that need a half or full hour of content.

CLICK HERE to watch the Laurence Fishburne segment.
(https://player.vimeo.com/video/473878358)


In addition to this, Allied has produced an additional piece that communicates the full Allied Corp vision and story. This content is contained in the link below.

CLICK HERE to watch the Allied Corp vision and story.
(https://vimeo.com/466210558)

“Being able to distribute the Allied message to the Behind the Scenes’ national network will only scale the number of people who we are able to reach with this important message” says Calum Hughes, CEO of Allied. “If you need some support, please reach out to us on social media or via our website.”

For more information on Allied Corp www.allied.health

About Allied Corp.
Allied Corp. is an international medical cannabis production company with a mission to address to-day’s medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.

Investor Relations:
[email protected]
1-877-255-4337

Forward-Looking Statements:

This press release contains “forward-looking information” within the meaning of applicable securi-ties laws in Canada or “forward-looking statements” made pursuant to the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and antici-pated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “esti-mate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circum-stances. Forward looking statements in this press release include the following: that Allied is lever-aging the conditions in its Colombia grow operation and future Kelowna location to support its Re-search and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufactur-ing, and introduction of TACTICAL RELIEF™ branded products, and the use of proceeds from the offering of convertible notes.

There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking in-formation in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of cur-rently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or in-vestor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its em-ployees, contractors, consultants and others; that the Company may experience breaches of securi-ty at its facilities or losses as a result of the theft of its products; risks related to the Company’s in-formation technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellec-tual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profita-ble; as well as any other risks that may be further described in and the risk factors discussed in the Company's continuous disclosure including its Management's Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company's profile at www.sec.gov.

Although management has attempted to identify important risk factors that could cause actual re-sults to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presen-tation. The Company disclaims any intention, obligation or undertaking to update or revise any for-ward-looking information, whether as a result of new information, future events or otherwise, ex-cept as required under applicable securities laws.

Company Contact Information:

Company: Allied Corp
Contact Name: Calum Hughes
Contact Phone: 2508788054
Contact Email: [email protected]
Company Website: www.allied.health
228716

Submit a Press Release

Submit your press release to the Castanet Press Room to communicate your message to the Okanagan's largest online audience. With over 380,000 unique visitors weekly, the Press Room is an effective way to make an announcement with impact.

Disclaimer: All press releases are reviewed by Castanet staff before going live. From the time you submit your press release, please allow up to 48 hours for your release to go live.

Submit a Press Release
232600